Sesardic D, Winsnes R, Rigsby P, Gaines-Das R
Division of Bacteriology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
Biologicals. 2001 Jun;29(2):107-22. doi: 10.1006/biol.2001.0282.
We report here the characterisation of a preparation of diphtheria toxoid, adsorbed, and its calibration by twenty laboratories in fourteen countries in terms of the Second International Standard (I.S.) for Diphtheria Toxoid, Adsorbed, coded sample A (DIXA) using the established World Health Organisation (WHO)/European Pharmacopoeia (Ph Eur) challenge methods. The replacement standard preparation was found to have a unitage of 160 IU/ampoule on the basis of its calibration by in vivo bioassay. Stability was assessed within the collaborative study, and as part of candidate characterisation. Results suggest that the replacement standard will have satisfactory stability. This study also provided an opportunity to investigate serology as alternative to in vivo bioassay for potency testing of diphtheria vaccines. Six laboratories participated by performing serology according to in-house protocol. The calibration of the replacement standard in a mouse Vero cell assay gave a significantly higher results than in the established WHO/Ph Eur methods. Based on the results of this study and with the agreement of participants, the candidate standard was established as the Third International Standard for Diphtheria Toxoid, Adsorbed (coded 98/560) by the WHO Expert Committee of Biological Standardization in October 1999. The same preparation was also established as the second Ph Eur Biological Reference Preparation (Ph Eur BRP, batch no. 3) by the Steering Committee of the Biological Standardisation Programme of the European Directorate for the Quality of Medicines and approved by the European Pharmacopoeia Commission.
我们在此报告吸附白喉类毒素制剂的特性描述,以及由14个国家的20个实验室依据吸附白喉类毒素第二国际标准(I.S.),采用世界卫生组织(WHO)/欧洲药典(Ph Eur)既定的效价测定方法,对编码为样本A(DIXA)的该制剂进行的校准。通过体内生物测定法校准,发现替代标准制剂的效价为160 IU/安瓿。在协作研究中以及作为候选特性描述的一部分对稳定性进行了评估。结果表明替代标准将具有令人满意的稳定性。本研究还提供了一个机会,来研究血清学方法作为白喉疫苗效价检测体内生物测定法的替代方法。六个实验室按照内部方案进行血清学检测参与了研究。在小鼠Vero细胞试验中对替代标准的校准结果明显高于既定的WHO/Ph Eur方法。基于本研究结果并经参与者同意,该候选标准于1999年10月被WHO生物标准化专家委员会确立为吸附白喉类毒素第三国际标准(编码98/560)。同一制剂还被欧洲药品质量理事会生物标准化计划指导委员会确立为欧洲药典第二个生物参考制剂(Ph Eur BRP,批号3),并获欧洲药典委员会批准。